Selenium as a marker of cancer risk and of selection for control examinations in surveillance

Marcin Lener1, Magdalena Muszyńska1-2, Anna Jakubowska1-2, Katarzyna Jaworska-Bieniek1, Grzegorz Sukienicki1, Katarzyna Kaczmarek1, Katarzyna Durda1, Tomasz Gromowski1, Pablo Serrano-Fernández1, Józef Klodny1, Anna Wiechowska-Kozłowska1, Tomasz Grodzki1, Ewa Jaworowska1, Jakub Lubiński1, Barbara Górecka-Szyld1, Grażyna Wilk1, Tomasz Byrski1, Cezary Cybulski1, Jacek Gronwald1, Tadeusz Dębiak1, Olgi Jerzy Ashuryk1, Aleksandra Tołoczko-Grabarek1, Antoni Morawski1,2, Rodney J. Scott1, Jan Lubiński1,2

1Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
2Read-Gene SA, Grzepnica, Poland
3Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
4Laboratory of Endoscopy, Division of Health Care, Ministry of Internal Affairs and Administration in Szczecin, Poland
5Specialised Hospital for Lung Diseases, Szczecin-Zdunowo, Poland
6Department of Otolaryngology and Laryngological Oncology, Pomeranian Medical University, Szczecin, Poland
7Department of General and Dental Radiology, Pomeranian Medical University, Szczecin, Poland
8Institute of Inorganic Chemical Technology and Environmental Engineering, West Pomeranian University of Technology, Szczecin, Poland
9Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle and The Hunter Medical Research Institute, Newcastle, New South Wales, Australia

Selenium as a marker of selection for control examinations in surveillance

There are literature data which clearly demonstrate that identification of low selenium levels can be useful in disease surveillance by such methods as computerised tomography for detection of lung cancers and in colonoscopy for detection of early stage colorectal cancers. More than 20 studies have shown that low serum selenium levels are related to an increased risk of lung cancer. Studies performed by our centre, which evaluated the level of selenium in the serum of 86 patients with lung cancer and 86 healthy controls, have also shown a strong correlation between selenium level and cancer. Among lung cancer cases, the mean selenium level was 63.2 µg/l compared to a mean level of 74.6 µg/l for their matched controls. A 10-fold reduced risk of lung cancer was also observed in individuals with serum selenium > 80 µg/l as compared to those patients whose serum Se levels were < 60 µg/l [1]. Between 2008-2011 in Szczecin – a single city of four hundred thousand inhabitants in North-West Poland – a programme for early detection of lung cancer was conducted. The enrolment criteria included both sexes, aged 55–65 years, who had a history of at least 20 pack-years of tobacco smoking. The latest addition to the protocol of this programme in 2012 was the inclusion of preselection of participants by measurement of their serum selenium levels. Only individuals with a low selenium level (< 75 µg/l) were invited for computerised tomography scans. This new addition to the protocol resulted in more than doubling the detection rate of lung cancers [2].
There are also about 10 studies that suggest a protective effect of selenium on colorectal adenoma/carcinoma development. In a Polish-Estonian study that evaluated the effect of selenium on the risk of colorectal cancer in 169 cancer cases and 169 healthy controls, a more than 13-fold increased risk of colorectal cancer was found in patients with serum Se levels < 40 µg/l compared to patients whose serum Se levels were > 72 µg/l [3].

Generally, there appears to be little doubt that low selenium level is associated with increased risk of cancer; however, the optimal serum selenium levels can be different for particular populations/countries. For example, in the U.S. the serum level of selenium associated with the lowest risk of colorectal adenomas is > 150 µg/l. Such differences between Europe and America can be related to several genetic and environmental factors including exposure to chemical compounds [4].

It is well recognised that for early colorectal cancer detection, colonoscopy is a well-established method for the detection of precancerous conditions and of early cancers. Screening studies using colonoscopy are not widely performed in the world as they are expensive and time consuming. It appears that pre-selection using data based on the levels of serum selenium may be useful in increasing the cost-effectiveness and specificity of detecting precancerous lesions occurring in the colon.

Further investigations are needed to determine the value of serum selenium levels as a selection marker for patient selection for prophylactic screening in other types of tumours, such as cancers of the stomach, pancreas, and prostate.

Selenium and cancer risk

Data from a meta-analysis of 49 prospective studies revealed that overall the risk of colorectal cancer incidence was 31% lower in the highest category of selenium exposure than in the lowest. Reduction of the number of new cases of cancers with optimised selenium concentration was observed for cancers of the: bladder, lung, larynx, prostate, stomach and colon [5].

In prospective cohort in our Polish centre we found similar correlation for non-breast cancers. In Table 1 we present results on prospectively found 95 cancer (including 19 prostate, 15 colorectal, 14 bladder, 11 lung cancers), matched (by sex, year of birth, cancer family history) 1 : 2 to unaffected individuals with a mean follow-up 19.4 months (range 3–45 months). A few-fold higher risk of cancer can be seen when serum selenium level is under 65 µg/L. There exists significant evidence that selenium levels may be used as a marker for high cancer risk patient groups and in the selection of persons for appropriate screening and early detection of tumours.

In summary, there exists significant evidence that selenium levels may be used as a marker for high cancer risk patient groups and in the selection of persons for appropriate screening and early detection of tumours.

The authors declare no conflict of interest.

References

1. Jaworska K, Gupta S, Durda K, Muszyńska M, Sukienicki G, Jaworowska E, Grodzieki T, Sulikowski M, Wołoszyk P, Wójcik J, Lubiński J, Cybulski C, Dębniak T, Lener M, Morawski AW, Krzystolik K, Narod SA, Sun P, Lubiński J, Jakubowska A. A low selenium level is associated with lung and laryngeal cancers. PLoS One 2013; 8: e59051.
2. Grodzieki T, Wójcik J, Jakubowska A, Wójcik R, Muszyńska M, Kubisa B, Jaworska-Bieniek K, Pieróg J, Gupta S, Alchimowicz J, Gromowski T, Jankowski H, Lubiński J. Low selenium serum level is a good preselection factor for patients invited for low dose chest CT lung cancer screening programme. International Association for the Study of Lung Cancer (IASLC). 15th World Conference on Lung Cancer. October 27-31, 2013, Sydney, Australia. Abstract MO11.13.
3. Lener MR, Gupta S, Scott RJ, Tootsi M, Kulp M, Tammesoo ML, Viitak A, Metspalu A, Serrano-Fernández P, Kladny J, Jaworska-Bieniek K, Durda K, Muszyńska M, Sukienicki G, Jakubowska A, Lubiński J. Can selenium levels act as a marker of colorectal cancer risk? BMC Cancer 2013; 13: 214.
4. Ou Y, Jiang B, Wang X, Ma W, Guo J. Selenium and colorectal adenomas risk: a meta-analysis. Nutr Cancer 2012; 64: 1153-9.
5. Dennert G, Zwhelen M, Brinkman M, Vinceti M, Zeegers MP, Horner M. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (5): CD005195.

Address for correspondence

Marcin Lener
Department of Genetics and Pathology
International Hereditary Cancer Centre
Pomeranian Medical University
Polabska 4
70-115 Szczecin, Poland
phone +48 91 466 15 32
fax +48 91 466 15 33
email: marcinlener@poczta.onet.pl

Table 1. The correlation between serum selenium level and the risk of cancers of different sites of origin

| Cancer                     | Quartile | Selenium level (µg/l) | No. of cancer/controls | OR   | p-value |
|----------------------------|----------|-----------------------|------------------------|------|---------|
| Any except of breast cancers | I        | < 65                  | 22/16                  | 1    | –       |
|                            | II       | 65–79                 | 38/87                  | 3.148| 0.0036  |
|                            | III      | 80–95                 | 28/61                  | 2.996| 0.0094  |
|                            | IV       | > 95                  | 3/21                   | 9.625| 0.0005  |